HEALTHCARE

Teva's share price reached a level last seen a decade ago after it announced FDA approval for once-monthly injection Weltruza.

Dr. Shimon Eckhouse is chairperson of the company, which developed a device to protect against embolisms during heart procedures.

Israeli-Palestinian cooperation on pharmaceuticals is worth examining, not as a peace project, but as an economic opportunity for both sides.

The Israeli pharmaceutical company today reported its plan to issue senior notes, denominated in euros and US dollars.

Former Bristol Myers Squibb executive Samuel Moed and Compugen chairperson Dr. Anat Cohen-Dayag are leading the Israel National Biotech Innovation Center.

1,300 doctors left Israel between 2023 and 2025, representing 3% of all the doctors employed in Israel, a new study by Tel Aviv University researchers has found.

The Ministry of Health preferred that Clalit own over 50% of the hospital and vetoed private deals.

The antibody TEV ‘408 (anti-IL 15) was also tested as a treatment for the skin disease vitiligo, and there it also presented encouraging findings.

The Israeli pharmaceutical company’s stock has risen 20% over the past month.

The advantage of InraGel's gel for treating cancer is that it can be injected and is biodegradable inside the body.

The company’s solutions allow life sciences enterprises to move away from designing clinical trials based on subjective assumptions toward launching trials that have been tested, optimized, and de-risked.

The Israeli pharmaceutical company sees higher than expected sales of Austedo, Ajovy and Uzedy in 2026.

The new funds from the private placement will finance the company until 2030.

The company, a developer of cancer treatments using electric fields, handily beat the analysts on the top and bottom line, and reported success with new products.

The new three-year agreement for the supply of normal source plasma from Kamada's plasma collection centers in Texas will produce about $50 million in revenue over three years.

Despite the recent losses, analyst Ori Hershkovitz sees a 31% upside in the Israeli pharmaceutical company’s share price.

The German company will implement layoffs in Jerusalem and Rehovot.

The Israeli company’s AI model can analyze brain activity measured by non-invasive means and turn it into quantitative metrics designed to help doctors and researchers make diagnoses.

Private equity firm FIMI bought control of pharmaceuticals company Rafa Laboratories from the Sackler family in 2020.

Assaf Rappaport and the other Wiz founders seek to buy 25% of Herzliya Medical Center at a NIS 1 billion valuation, and a similar offer from Yitzhak Tshuva is still open, but regulation may thwart both contenders.

The Israeli company reported in the study that patients showed improvements in skin pigmentation with vitiligo.

IATI's annual report for 2025 portrays general stagnation in the Israeli industry. with one or two bright spots.

The investment comes following positive results in an initial efficacy trial, Phase IIa, in which an improvement in lung function was demonstrated in some 70% of patients.

The donation by the Jusidman family of Mexico will enable the Reuth Association to build its new rehabilitation hospital at Sde Dov.

Oran Holtzman's online cosmetics company was riding very high indeed until it hit a snag with its main advertising partner.

Teva had been in talks to sell its active pharmaceutical ingredients activity but a deal never materialized.

Former Teva CEO Jeremy Levin has published a sobering critique of a critical industry. He talks to "Globes" about his conclusions, and how Israel should act.

Dr. Marc Abitbol, who founded Jerusalem-based Visionix in 1994, tells “Globes” why he has finally decided to sell the eye care company and step down as CEO.

The company’s share price opened 22% higher today on Wall Street, giving a market cap of $984.5 million.

Reichman University’s Prof. Yosi Shacham-Diamand is developing chips that monitor plants, detect hazards in drinking water, and help medical teams treat wounded soldiers. Now he has an ambitious new vision.